- Lobbying
- Lobbying by Dr. Emil Kakkis
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Jeanne Haggerty | Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member |
Laura Simmons | Advisor, Office of Legislative Affairs, Dept of Homeland Security |
Kurt Schrader | Former Member of Congress |
Karina Lynch | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
Alec Aramanda | Prof Staff, House Cmtee on E&C; Dir Ofc of Legislation & Dir Stakeholder Engagement, Centers for Medicare & Medicaid Services; Deputy Assistant Secretary for Health Policy, Department of Health & Human Services; Domestic Policy Advisor, Deputy Legislative Director, Leg Asst, Sen. Cruz; Leg Asst, Sen. DeMint. |
Susan Hirschmann | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: FDA drug approval process for rare diseases, including increased use of biomarkers in the Accelerated Approval Pathway, clinical trial design and other barriers to approval..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate